JNJ-JOHNSON & JOHNSON

Johnson & Johnson Sues Samsung Bioepis Over Biosimilar Launch Amidst Competitive Pressure and Ongoing Focus on Innovation and Growth

Member Only Article

Thursday

27 February, 2025

Johnson & Johnson is facing a pivotal moment as it battles Samsung Bioepis over the launch of a biosimilar for its blockbuster drug Stelara, amidst a backdrop of fierce competition and recent setbacks in its vaccine trials. Can J&J maintain its status as a Dividend King while navigating these turbulent waters?

article image for JNJ

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
0
Key Takeaways
  • Loading...

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.